article thumbnail

Opinion: The FDA’s risky action on compounding weight loss drugs

STAT

When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost.

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone. Adverse Drug Reactions (ADRs) Adverse drug reactions are a major concern in polypharmacy. Each additional medication increases the risk due to the cumulative effect of multiple drugs.

article thumbnail

New approvals to revolutionise myelofibrosis treatment landscape across 8MM: GlobalData

Express Pharma

billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 Jakafi’s landmark approval in 2011 galvanised intensive drug development efforts by providing a strong positive investment signal for this market, as Jakafi is a blockbuster agent. billion in 2021 to $2.89

article thumbnail

Alfacalcidol and Calcitriol

RX Note

Introduction Vitamin D is a range of compounds which possess the property of preventing or curing rickets. The previous 2011 product monograph recommended that the drops be keep refrigerated (2-8°C) and use within 28 days of first opening the bottle.

article thumbnail

Dilution Protocol

RX Note

ASHP Injectable Drug Information, 2022 Australian Injectable Drug Handbooks, 2020 - free trial is available Davis's Drug Guide for Nurses, 2022 Elsevier's 2023 Intravenous Medications, 2022 External Stability for Parenteral Drugs, 2022 GlobalRPh IV Dilutions Medication Reference and Infusion Guidelines Injectable Drugs Guide, 2011 King Guide Pediatric (..)

article thumbnail

Pulse Infoframe Releases Registry for Patient Advocacy Groups

pharmaphorum

Since 2011, the company has been designing solutions that accelerate rare disease research and create lasting inter-sector partnerships across the globe. Rare Central also benefits sponsors and the wider pharmaceutical industry.